CR Group L.P. - 03 Jul 2023 Form 4/A - Amendment Insider Report for T2 Biosystems, Inc. (TTOO)

Role: 10%+ Owner
Signature: /s/ Nathan D. Hukill, authorized signatory for CRG Partners III L.P., CRG Partners III Parallel Fund (A) L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund (B)(Cayman) L.P.
Issuer symbol: TTOO
Transactions as of: 03 Jul 2023
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 14 Jul 2023, 18:57:39 UTC
Date Of Original Report: 06 Jul 2023
Next filing: 09 Aug 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TTOO	Series B Convertible Preferred Stock	Award		+33,595			33,595	03 Jul 2023	Common Stock	33,595,000	$0.0706	By CRG Partners III (Cayman) Lev AIV I L.P.	F1, F2, F3
transaction	TTOO	Series B Convertible Preferred Stock	Award		+59,703			59,703	03 Jul 2023	Common Stock	59,703,000	$0.0706	By CRG Partners III Parallel Fund (B) (Cayman) L.P.	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The acquisition of these shares was inadvertently omitted from the reporting persons' Form 4 filed with the SEC on July 6, 2023.
F2	Each share of Series B Convertible Preferred Stock (the "Series B Preferred") converts into 1,000 shares of the Company's common stock at the holder's election, subject to beneficial ownership limitations, including that a holder of Series B Preferred is prohibited from converting such shares into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. As a result of the 19.99% beneficial ownership limitation, as of July 3, 2023, the Series B Preferred held by the reporting persons can be converted into a maximum of 24,157,794 shares of common stock in the aggregate. The shares of Series B Preferred have no expiration date.
F3	Pursuant to that certain Securities Purchase Agreement, dated July 3, 2023, by and among the Company, CRG Partners III L.P., CRG Partners III - Parallel Fund "A" L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund "B" (Cayman) L.P. (collectively, the "CRG Entities"), the CRG Entities received these shares in exchange for the CRG Entities surrendering for cancellation of certain outstanding debt.